As the CEO of Dyne Therapeutics, Thomas W. Elward has fluctuated holdings that reflect his deep connection to the company's performance. Over the years, his stock holdings have spiked and dipped significantly. For example, at the peak of his career...

As the CEO of Dyne Therapeutics, Thomas W. Elward has fluctuated holdings that reflect his deep connection to the company's performance. Over the years, his stock holdings have spiked and dipped significantly. For example, at the peak of his career in 2016, his compensation, coupled with vested stocks, hit around $8.3 million. However, in recent years, the total compensation dropped to around $756,786 in 2023, indicating a careful alignment with corporate goals and performance. The stock price itself has seen a varied history; it was $899.75 in September 2020 but dropped to lows around $228.51 in June 2022. Currently, it's valued around $492.53. This shift shows the volatility of the stock market and its impact on executive holdings, but Elward’s significant ownership indicates his commitment to navigating these ups and downs for company success. Through significant variances, his connection to the company's health remains paramount, illustrating the blend of risk and reward that comes with leadership in this sector.